Original Clinical Science

The Perioperative Management of Patients Undergoing Combined Heart-Liver Transplantation David W. Barbara,1 Kent H. Rehfeldt,1 Julie K. Heimbach,2 Charles B. Rosen,2 Richard C. Daly,2 and James Y. Findlay Background. Combined heart-liver transplantation (CHLT) is an uncommonly performed procedure for patients with coexisting cardiac and liver disease. Methods. A retrospective review was performed of patients undergoing CHLT at our institution from 1999 to 2013. Information related to preoperative organ function, intraoperative management, surgical approach, transfusions, postoperative findings, and 30-day mortality was reviewed. Results. Twenty-seven CHLT were performed, with 4 of the 27 including simultaneous kidney transplantation. Familial amyloidosis was the indication for 21 CHLTs (78%), and 12 of these explanted livers were used for domino transplantations. Nineteen patients (70%) were receiving inotropic infusions at the time of organ availability. Median preoperative model for end-stage liver disease score was 12. Liver transplantation immediately preceded cardiac transplantation in 2 of the 27 cases because of the presence of high titer donor-specific antibodies and the potential of the liver to lead to a reduction in the antibody titer. Venovenous bypass was used in 14 operations (52%) which were performed with the caval interposition approach to liver transplantation, cardiopulmonary bypass during liver transplantation in two cases (7%), and no bypass in 11 operations (41%) performed with caval sparing (piggyback) surgical technique. Postoperatively, median duration of mechanical ventilation, intensive care unit stay, and hospital stay until discharge were 1 day, 5.5 days, and 15 days, respectively. Transfusions in the first 48 hr after CHLT were not substantial in most patients. One patient died within 30 days of CHLT. Conclusion. Combined heart-liver transplantation is a life-saving operation that is performed with relatively low mortality and can be successfully performed in select patients with congenital or acquired cardiac disease.

(Transplantation 2015;99: 139–144)

C

ombined heart-liver transplantation (CHLT) is an uncommonly performed and potentially life-saving operation. Initially reported in 1984, the first published CHLT involved a 6-year-old female with severe familial hypercholesterolemia and heart failure secondary to coronary artery disease.1 Reported indications for CHLT have evolved to include (1) end-stage cardiac and liver disease because of related causes, (2) end-stage cardiac and liver disease from unrelated causes, and (3) end-stage heart disease with liver transplantation performed to correct an underlying disorder.2,3 To date, 163 CHLTs (141 CHLTs, 13 combined heartliver-kidney, and 12 combined heart-liver-lung) have been Received 21 January 2014. Revision requested 21 February 2014. Accepted 10 April 2014. 1

Department of Anesthesiology, Mayo Clinic College of Medicine, Rochester, MN.

2

Department of Surgery and William J. von Liebig Transplant Center, Mayo Clinic College of Medicine, Rochester, MN.

performed in the United States (The Organ Procurement and Transplantation Network National Data Transplantation Reports, Dec 11, 2013, http://optn.transplant.hrsa.gov/ latestData/step2.asp?). Graft survival after CHLT is similar to isolated liver or heart transplantation, exceeding 80% at 1 year and 70% at 10 years.2,4 Combined heart-liver transplantation has been described in case reports and retrospective series that focused largely on operative technique and outcomes. Prior reports examining perioperative management from other institutions contain a relatively small number of cases (1–6 CHLT operations).5-10 Our institution previously reported on long-term outcomes after CHLT, early and late graft function, rejection, and immunosuppressive therapy.11 The purpose of this study was to examine and describe the perioperative management of patients undergoing CHLT at a single institution with a relatively large experience in performing this procedure.

The authors declare no funding or conflicts of interest. D.W.B. participated in research design, writing of the article, performance of the research, and data analysis. K.H.R. participated in research design and writing of the article. J.K.H. participated in research design and writing of the article. C.B.R. participated in research design and writing of the article. R.C.D. participated in research design and writing of the article. J.Y.F. participated in research design, writing of the article, performance of the research, and data analysis. Correspondence: David W. Barbara, MD, Mayo Clinic, 200 First Street S.W., Rochester, MN. ([email protected]) Copyright © 2014 Wolters Kluwer Health, Inc. All rights reserved. ISSN: 0041-1337/15/9901-139 DOI: 10.1097/TP.0000000000000231

Transplantation



January 2015



Volume 99



Number 1

RESULTS Twenty-seven patients underwent CHLT, with 4 of the 27 patients undergoing simultaneous kidney transplantation. Mean age at time of transplantation was 53.8±9.7 years (median, 57 years; range, 29–66 years), and 16 of the 27 patients (59%) were men. Preoperative findings are listed in Table 1. A wide variety of echocardiographic findings were present preoperatively (Table 2). No patient had undergone prior heart or liver transplantation. One patient had received dialysis within 1 week before CHLT. www.transplantjournal.com

Copyright © 2014 Wolters Kluwer Health, Inc. All rights reserved.

139

140

Transplantation



January 2015



Volume 99



Number 1

Seven patients received preoperative transfusions within 24 hr of CHLT. Preoperative transfusions consisted of fresh frozen plasma (range, 1–3 units) given for reversal of warfarin anticoagulation (four patients), for plasma exchange and

www.transplantjournal.com

TABLE 2.

Preoperative transthoracic echocardiographic findings in patients undergoing combined heart-liver transplantation

LV size

TABLE 1.

Preoperative findings for 27 patients undergoing combined heart-liver transplantation

Cardiac transplantation indication

Liver transplantation indication NYHA functional classification

Receiving inotropic infusions at time of organ availability Receiving warfarin at time of organ availabilityb MELD scorec Inpatient at time of organ availability Cardiac rhythmd

Previous cardiac surgery requiring sternotomy Previous upper abdominal surgery Ascites present Hemoglobin, g/dL Platelet count, ×109/L Bilirubin, total, mg/dL International normalized ratiob Creatinine, mg/dL Body mass index, kg/m2 a

21 (78%) familial amyloidosis 2 (7%) congenital heart disease 2 (7%) idiopathic restrictive cardiomyopathy 1 (4%) apical variant hypertrophic cardiomyopathy 1 (4%) arrhythmogenic right ventricular dysplasia 21 (78%) familial amyloidosis 6 (22%) congestive hepatopathy 3 (11%) II 5 (19%) III 19 (70%) IV 19 (70%) yesa 8 (30%) no 7 (26%) yes 20 (74%) no Mean, 12 ± 4.7, median, 11; range, 6-23 14 (52%) yes 13 (48%) no 16 (59%) sinus rhythm 6 (22%) atrial fibrillation/flutter 4 (15%) paced 1 (4%) supraventricular tachycardia 7 (26%) yes 20 (74%) no 2 (7%) yes 25 (93%) no 14 (52%) yes 13 (48%) no Mean, 12.3 ± 1.8; median, 12.2; range, 9.4-16.1 Mean, 181 ± 53; median, 178; range, 94-342 Mean, 1.1 ± 0.5; median, 1.1; range, 0.3-2.1 Mean, 1.4 ± 0.6; median, 1.1; range, 0.9-3.6 Mean, 1.3 ± 0.5; median, 1.1; range, 0.5-2.6 Mean, 25.1 ± 3.5; median, 25.1; range, 18–33

Inotropic infusions consisted of milrinone and dopamine in nine patients, milrinone in six patients, dopamine and dobutamine in two patients, dobutamine in one patient, and dopamine in one patient. Only one patient (with familial amyloidosis) with an abnormal INR (1.4) was not taking warfarin at the time of organ availability. The 19 other patients not receiving warfarin at time of organ availability demonstrated INR results within the normal reference range: 0.8-1.2. c MELD score of 21 patients with familial amyloidosis: mean, 12±5; median, 12; range, 6-23. MELD score of familial amyloidosis patients excluding five patients on warfarin with elevated INRs: mean, 10±4; median, 9; range, 6-18. MELD score of all CHLT patients excluding seven patients on warfarin with elevated international normalized ratios: mean, 10±4; median, 9; range, 6-19. MELD score of six patients without amyloidosis: mean 11±5, median 9, range 7-19. MELD score of 12 amyloidosis patients whose livers were used for domino transplantations: mean, 12±5; median, 11; range, 6-18. d As determined by electrocardiogram. INR, international normalized ratio; MELD, model for end-stage liver disease; NYHA, New York Heart Association; CHLT, combined heart-liver transplantation. b

Ejection fraction (%) Diastolic function RV size

RV function

Right ventricular systolic pressure (mmHg) Valvular abnormalitiesa

LVAD present at time of CHLT

5 (18%) small LV cavity 18 (67%) normal 3 (11%) mild enlargement 1 (4%) moderate enlargement Mean, 42±17; median, 45; range, 15-75 13 (48%) restrictive 14 (52%) indeterminate 19 (70%) normal 3 (11%) mild enlargement 1 (4%) mild-moderate enlargement 2 (7.5%) moderate enlargement 2 (7.5%) moderate-severe enlargement 8 (30%) normal 6 (22%) mild dysfunction 4 (15%) mild-moderate dysfunction 5 (19%) moderate dysfunction 2 (7%) moderate-severe dysfunction 2 (7%) severe dysfunction Mean 41±10, median 42, range 26-58 15 (56%) none 9 (33%) tricuspid regurgitation 2 (7%) mitral regurgitation 1 (4%) tricuspid regurgitation and pulmonary regurgitation 1 (4%)

a Valvular abnormalities ≥ moderate severity as determined by transthoracic echocardiogram. CHLT, combined heart-liver transplantation; LV, left ventricular; LVAD, left ventricular assist device; RV, right ventricular.

warfarin anticoagulation reversal (2 patients), or for plasma exchange without preoperative warfarin use (one patient). Three patients underwent preoperative plasma exchange for donor-specific antibodies. Details related to intraoperative management are listed in Table 3. Vascular access consisted of radial and femoral arterial lines and a 9 Fr introducer with a pulmonary artery catheter placed in the internal jugular vein in all cases. Additionally, all cases used an additional 8.5 Fr quad lumen central line, 8.5 Fr single lumen cannula inserted into an internal jugular vein, and 1–2 8.5 Fr peripheral venous catheters in the antecubital fossae. Transesophageal echocardiograms were performed in all patients. No patient required an intraaortic balloon pump intraoperatively. Intraoperative anesthetic management consisted of a teambased approach with separate cardiac and liver transplantation anesthesia teams involved during transplantation of respective organs. After induction of anesthesia and endotracheal intubation, anesthesia was maintained with isoflurane in air or oxygen. Neuromuscular blockade was maintained with cisatracurium, vecuronium, or pancuronium. Inotropic and vasoactive infusions present 10 min after cardiopulmonary bypass (CPB) separation after cardiac transplantation and 10 min after liver graft recirculation are listed in Table 4. Ten minutes after CPB separation after cardiac transplantation, two patients were receiving inhaled nitric oxide and two inhaled alprostadil. Ten minutes after liver graft recirculation, seven patients were receiving inhaled nitric oxide and two inhaled alprostadil.

Copyright © 2014 Wolters Kluwer Health, Inc. All rights reserved.

Barbara et al

© 2014 Wolters Kluwer

141

TABLE 3.

Intraoperative management of patients undergoing combined heart-liver transplantation

Order of operation

25 (93%) heart transplantation before liver transplantation 2 (7%) liver transplantation before heart transplantation 11 (41%) none 14 (52%) venovenous bypassa 2 (7%) cardiopulmonary bypass 14 (52%) caval interposition 13 (48%) caval sparing (piggyback) 6 (22%) none 8 (30%) aminocaproic acid 8 (30%) aprotinin 5 (18%) tranexamic acid Mean, 760±125; median, 754; range, 545-1124 Mean, 141±57; median, 142; range, 58-257 Mean, 390±104; median, 413; range, 151-536 Mean, 134±40; median, 122; range, 82-244 Mean, 62±11; median, 61; range, 45-82 Mean, 7.7±5.8; median, 6.0; range, 1-26 Mean, 2.0±1.2; median, 1.8; range, 0.5-6.8 Mean, 7.7±4.9; median, 7.0; range, 0-23 Mean, 2.5±2.1; median, 2.0; range, 0-8 Mean, 1.7±1.9; median, 1.0; range, 0-6

Use of bypass for liver transplantation

Caval interposition or sparing technique used for liver transplantation Antifibrinolytic use

Duration of operationb, min Donor heart ischemic time, min Donor liver ischemic time, min Cardiopulmonary bypass duration, min Anhepatic period duration, min Red blood cell transfusion, units Autologous cell salvage use, L Fresh frozen plasma transfusion, units Platelet transfusion (apheresis units) Cryoprecipitate transfusion (number of pooled units administered) a b

Venovenous bypass consisted of a double-limb (femoral and portal vein) inflow with a dedicated internal jugular outflow cannula. As derived from the anesthesia billing start and end times.

Twelve explanted livers from patients with familial amyloidosis undergoing CHLT were used for domino liver transplantations. The liver transplantation portions of these 12 CHLTs were performed using the caval interposition technique and venovenous bypass (VVB). Two additional patients (one familial amyloidosis and one idiopathy cardiomyopathy with congestive hepatopathy) underwent CHLT using the caval interposition liver transplantation approach and VVB. The livers were not used for domino transplantation because of advanced fibrosis. Eleven patients underwent CHLT using the piggyback (caval sparing) liver transplantation technique without VVB. In two patients, CPB was used during transplantation of both the heart and liver (both using piggyback liver transplantation techniques). One case, previously reported in detail, involved liver transplantation before cardiac transplantation to protect the cardiac graft from high titer donor-specific antibodies.12 Cardiopulmonary bypass was initiated during the anhepatic phase before hepatic reperfusion to facilitate reduction in hepatic venous pressure for the liver graft. The second case involved a donor who sustained a cardiac arrest during organ retrieval because of hemorrhagic shock and was placed on CPB in an attempt to improve cardiac function. Cardiac transplantation followed by liver transplantation was performed in the recipient also using CPB to minimize any hemodynamic disturbances to the organ grafts during transplantation, given the donor instability. In two patients, the liver graft was transplanted before the cardiac graft. One case was previously reported.12 The second patient was a 41-year-old female with apical variant hypertrophic cardiomyopathy, congestive hepatopathy, and high titers of preformed donor-specific anti–human leukocyte antigen (HLA) antibodies. Preoperative plasma exchange was performed. After sternotomy and exposure of

the recipient’s heart, the liver graft was transplanted first to protect the cardiac graft from donor-specific antibodies. Cardiopulmonary bypass was available at the time of hepatic reperfusion if hemodynamic instability arose; however, hepatic reperfusion was tolerated by the recipient’s native heart without the need for CPB or VVB. Postoperative management details are listed in Table 5. All patients were transferred to the intensive care unit (ICU) intubated, mechanically ventilated, and sedated. No patient required a tracheostomy. Five patients required dialysis postoperatively, none of whom were receiving dialysis preoperatively. No differences in perioperative outcomes were observed in patients with preoperative severe right ventricular dysfunction compared to normal right ventricular function. One death occurred within 30 days of CHLT, involving a 58-year-old female undergoing CHLT for familial amyloidosis (preoperative model for end-stage liver disease [MELD] score 6, left ventricular ejection fraction 53%, restrictive diastolic function, and normal right ventricular size and function) who suffered two intraoperative cardiac arrests during reperfusion of the liver and abdominal closure. After cardiac transplantation, liver transplantation was performed using caval interposition surgical approach and VVB without heparinization (activated clotting time 130 sec before VVB), as was our practice at that time. After hepatic graft recirculation and discontinuation of VVB, severe bleeding was encountered (hemoglobin nadir, 4.1 g/dL), followed by diffuse intravascular thrombosis including a left atrial thrombus that was subsequently noted on transesophageal echocardiography. Cardiopulmonary bypass was reinitiated, and the left atrial thrombus removed. Because of subsequent right ventricular failure, a right ventricular assist device was placed. Right ventricular assist device support was changed intraoperatively to venoarterial extracorporal membrane oxygenation that was

Copyright © 2014 Wolters Kluwer Health, Inc. All rights reserved.

142

Transplantation



January 2015



Volume 99



Number 1

TABLE 4.

Intraoperative inotropic and vasoactive infusions in patients undergoing combined heart-liver transplantation Inotropic infusions present 10 min after cardiopulmonary bypass (CPB) separation after cardiac transplantation

Epinephrine, isoproterenol, and milrinone Epinephrine, isoproterenol, and dopamine Epinephrine and isoproterenol Dopamine and isoproterenol Isoproterenol Isoproterenol and milrinone Dopamine, isoproterenol, and milrinone Dopamine Milrinone Drug infusions primarily altering afterload present 10 min after cardiopulmonary bypass (CPB) separation after cardiac transplantation Nitroprusside Norepinephrine Vasopressin Norepinephrine and vasopressin None Inotropic infusions present 10 min after liver graft recirculation Epinephrine, isoproterenol, and milrinone Epinephrine, isoproterenol, and dopamine Epinephrine and isoproterenol Isoproterenol Epinephrine Dopamine and isoproterenol Dopamine, epinephrine, isoproterenol, and milrinone Dopamine, isoproterenol, and milrinone Esmolol Milrinone None Drug infusions primarily altering afterload present 10 min after liver graft recirculation Nitroprusside Vasopressin Norepinephrine Phenylephrine None

9 4 4 3 3 1 1 1 1

9 3 3 1 11 6 4 4 3 3 2 1 1 1 1 1

8 7 1 1 10

continued postoperatively. Because of lack of neurologic recovery, multiple severe strokes on brain imaging, and multiorgan failure, care was withdrawn on postoperative day 3. No other patient suffered 30-day or in-hospital mortality.

DISCUSSION The main findings of this study are as follows: (1) most patients undergoing CHLT showed metabolic abnormalities, such as amyloid production and preserved hepatic function as evidenced by a median MELD score of 11, with preoperative coagulation abnormalities most commonly attributed to warfarin therapy; 2) the caval interposition liver transplantation technique with VVB was most often used for planned domino liver transplantations; 3) most patients postoperatively did not receive substantial transfusions, require prolonged mechanical ventilation, or experience 30-day mortality; 4) CHLT

www.transplantjournal.com

was successfully performed in patients with congenital or hereditary cardiac disease. Consistent with national data for CHLT, familial amyloidosis was the most common indication for transplantation (78% of cases) at our institution.2 Interestingly, four series focusing on perioperative management of CHLT reported that only 0% to 20% of their cases involved amyloidosis.5,6,8,9 Domino transplantation involves transplantation of the liver from a patient undergoing liver transplantation (or CHLT) for familial amyloidosis into another recipient (typically older than 60 years), with an expected lifespan shorter than the time required to develop symptoms from the production or deposition of amyloid by the transplanted liver. At our institution, domino liver transplantations were performed using 12 of the 21 livers (57%) from familial amyloidosis patients undergoing CHLT. Other reasons for CHLT included congenital or hereditary cardiac disease (15% of cases) or idiopathic cardiomyopathy (7% of cases). Liver transplantation was performed in 78% of CHLT cases to correct the underlying metabolic abnormality of familial amyloidosis and for congestive hepatopathy in the remaining cases (22%). Excluding patients receiving warfarin preoperatively, all our patients showed a normal international normalized ratio (INR) at the time of organ availability except for one patient with an INRx of 1.4. Patients with familial amyloidosis presenting for CHLT showed a preserved hepatic function. In patients without familial amyloidosis presenting for CHLT, median MELD score was 9 (range, 7–19). Combined heart-liver transplantation patients, especially in the setting of familial amyloidosis, commonly present with preserved hepatic function, as less severe liver disease is associated with improved survival to CHLT.7,13 However, the cardiac function at time of organ availability is typically compromised, as evidenced by the 30% requiring inotropic support at time of organ availability and preoperative echocardiographic findings including compromised systolic and diastolic function. In 25 of the 27 cases (93%), the cardiac graft was transplanted before the liver graft. Two operations (7%) were performed by transplanting the liver graft before the cardiac graft. This was performed, as previously reported, to allow the transplanted liver to absorb or neutralize high titer donor-specific HLA antibodies present in both recipients.12,14 Although the exact mechanism of reduction of donor-specific antibody after CHLT transplantation is unknown, theories include: phagocytosis of antibodies by Kupffer cells, HLA antigen secretion, or dilution of antibody concentrations caused by bleeding or a large vascular bed.15-19 Additionally, reduction in donorspecific HLA antibodies has also been observed after isolated liver and combined liver-kidney transplantations.17,18,20 Typically, cardiac transplantation precedes liver transplantation in patients undergoing CHLT given the decreased ischemic tolerance of the cardiac graft compared to the liver graft. When the liver is transplanted first, complex and careful planning is necessary to choreograph the donor and recipient procedures to minimize the cardiac ischemic time. Transplantation of the heart and liver grafts en bloc has been reported as well, but our institution has not used this operative approach.10 Various techniques have been successfully reported involving use of CPB, VVB, or no bypass for the liver transplantation portion of CHLT operations.5,6,8–10,21,22 Fourteen patients (52%) at our institution underwent liver transplantation using a caval interposition technique with VVB. The remaining

Copyright © 2014 Wolters Kluwer Health, Inc. All rights reserved.

Barbara et al

© 2014 Wolters Kluwer

143

TABLE 5.

Postoperative findings in patients undergoing combined heart-liver transplantation

Red blood cell transfusiona (units) Fresh frozen plasma transfusiona (units) Platelet transfusiona (apheresis units) Cryoprecipitate transfusiona (number of pooled units administered) Duration of mechanical ventilation, days Number of procedures performed before dischargeb Initial intensive care unit length of stay, days Hospital length of stay, days

Mean, 3.2 ± 5.4; median, 2.0; range, 0-26 Mean, 1.8 ± 5.0; median, 0; range, 0-24 Mean, 0.7 ± 1.6; median, 0; range, 0-7 Mean, 0.6 ± 2.1; median, 0; range, 0-8 Mean, 1.8 ± 2; median, 1; range, 1-11 Mean, 2.6 ± 4.1; median, 2; range, 0-19 Mean, 8.5 ± 7.1; median, 5.5; range, 2-33 Mean, 24.6 ± 27.8; median, 15; range, 8-134

a

Transfusions reported include those received within 48 hrs postoperatively. Procedures performed after transplantation included (1) commonly performed procedures after liver transplantation consisting of abdominal exploration, abdominal closure, endoscopic retrograde cholangiopancreatography±biliary stent placement, cholangiogram, and liver biopsy; (2) commonly performed procedures after cardiac transplantation including mediastinal exploration, chest closure, right ventricular biopsy, pericardiocentesis, permanent pacemaker placement, preexisting pacemaker generator removal, and transesophageal echocardiogram with cardioversion; and (3) other procedures consisting of dialysis catheter placement, inferior vena cava filter placement, esophagogastroduodenoscopy, and aortic-hepatic jump graft for hepatic artery stenosis. b

13 operations were performed with a piggyback approach with no bypass required (11 patients) or full CPB (2 patients). By preserving the recipient’s vena cava, the piggyback technique may eliminate the need for VVB and can be safely performed in most liver transplantations.23 Despite known complications of VVB, in cases of anticipated domino transplantation or anatomy rendering the piggyback technique difficult, this technique may mitigate hemodynamic instability and reduce portal or retroperitoneal venous hypertension during caval and portal vein occlusion.8,24,25 Subsequent to the CHLT patient who died after experiencing bleeding and diffuse intravascular thrombosis after liver transplantation with VVB without heparinization, our practice has changed to now heparinize patients for VVB with a goal activated clotting time of 180 to 220 sec. Before this case, our practice did not use heparinization for VVB. However, given the preserved synthetic liver function in the most CHLT patients and the potentially hypercoagulable state after discontinuation of CPB and heparin reversal with protamine, we believe that some degree of heparinization with VVB is advisable. Cardiopulmonary bypass was used in two cases for transplantation of both the heart and liver, both involving aforementioned unique circumstances. We do not routinely use this technique given the coagulopathy and inflammatory response associated with prolonged CPB times. However, the practice at some other institutions involves routine use of CPB during transplantation of both organs in all CHLT operations.21,22 These authors conclude that the risks of CPB during liver transplantation are outweighed by the decreased hemodynamic and metabolic disturbances with hepatic reperfusion, thereby lessening stress on the cardiac graft. Although various combinations of inotropic infusions were used after CPB separation after cardiac transplantation, these typically involve positive inotropic and chronotropic agents, such as epinephrine, isoproterenol, milrinone, and dopamine. Agents to alter systemic and pulmonary vascular resistance are added at the discretion of the anesthesiologist. After liver graft recirculation, the aforementioned inotropic support is typically continued with alteration in vasoactive infusions affecting systemic and pulmonary vascular resistance at the anesthesiologist’s discretion. Intraoperative transfusions are typically guided by point-of-care laboratory testing and a previously published goal-directed transfusion algorithm.26 Since the withdrawal of aprotinin from the United States 2007, antifibrinolytics currently used for CHLT procedures consist

of aminocaproic acid or tranexamic acid. As evidenced by 78% of patients receiving an antifibrinolytic, our practice favors antifibrinolytic agent administration for CHLT unless a contraindication exists (e.g., history of deep vein thrombosis, pulmonary embolism). Intraoperative antifibrinolytic therapy currently consists of a loading dose before incision followed by an infusion of tranexamic acid or aminocaproic acid. The postoperative courses of the most patients were relatively uneventful. Most patients did not require substantial transfusions in the first 48 hr after CHLT, with a median red blood cell transfusions of 2 units and median transfusion of platelets, fresh frozen plasma, and cryoprecipitate of 0 units. There were patients who remained significantly coagulopathic after CHLT and required more than 20 units of red blood cells and fresh-frozen plasma. Our median duration of mechanical ventilation, ICU stay, and hospital stay were relatively short at 1 day, 5.5 days, and 15 days, respectively, consistent with a recent series involving five CHLTs at a large academic center.6 However, as noted in this and other series, some patients will require prolonged mechanical ventilation, ICU stays, and hospital courses after CHLT. We credit the overall favorable postoperative courses and low 30-day mortality (1/27 patients) to the perioperative multidisciplinary approach to care received by CHLT patients at our institution. Limitations of this study include all those inherit to a retrospective study, including charting inaccuracies or unclear reasons for management decision. By definition, only patients undergoing CHLT during a single operation were included, and cases of planned or unplanned sequential transplantation are not included. Immunosuppressive therapy, early and late graft function, rejection, and long-term outcomes were not included, as these have previously been reported.11

CONCLUSION In conclusion, CHLT is a life-saving but uncommonly performed operation. Most patients have relatively preserved hepatic function preoperatively compared to the traditional liver transplantation patient. Cardiac function is typically significantly compromised. Although most commonly performed for familial amyloidosis, patients with acquired or congenital cardiac disease successfully underwent CHLT. A variety of operative and bypass techniques may be used successfully for completion of the liver transplantation portion of CHLT

Copyright © 2014 Wolters Kluwer Health, Inc. All rights reserved.

144



January 2015



Volume 99



Number 1

www.transplantjournal.com

operations. Overall, most patients experienced uneventful postoperative courses, and overall 30-day mortality was low.

Statistical analysis consisted of mean, standard deviation, median, and range determination for continuous variables and percent quantification for categorical variables.

Transplantation

MATERIALS AND METHODS This study was approved by the Mayo Foundation Institutional Review Board. All patients had provided prior written consent for use of their records for research purposes. A database of liver transplantation patients was searched for those patients who underwent simultaneous heart transplantation from January 1, 1999, to June 1, 2013. Individual patient records were then reviewed by one of the authors (D.W.B.) to verify the patient had undergone CHLT in a single operation. Patients undergoing heart and liver transplantations in separate operations were excluded. A standard data collection form was used. Demographic information (age at time of surgery and gender) was noted. Preoperative baseline information collected included cardiac and liver indications for transplantations, transplantations performed (CHLT, combined heart-liver-kidney transplantation), body mass index at time of surgery, transthoracic echocardiographic findings (left ventricular size, left ventricular ejection fraction, left ventricular diastolic function grade, right ventricular size, right ventricular function, right ventricular systolic pressure, cardiac valvular abnormalities>moderate in severity), presence of a left ventricular assist device at time of CHLT, cardiac rhythm on electrocardiogram, history of previous cardiac operation requiring sternotomy, history of prior upper abdominal operation, history of previous heart or liver transplantation, New York Heart Association functional classification, inpatient or outpatient at time of organ availability, presence and type of inotropic infusions at time of organ availability, presence of ascites, warfarin use at time of organ availability, if patient had received dialysis within 1 week of organ availability, laboratory values (platelet count, hemoglobin, creatinine, INR, total bilirubin), MELD score, transfusion within 1 day of transplantation, and plasma exchange. Intraoperative findings collected included duration of anesthesia (as calculated from anesthesia start and end times), intravascular access (placed by anesthesia providers), transesophageal echocardiogram utilization, order of transplantation (heart before liver or liver before heart), CPB duration, anhepatic phase duration, surgical approach to liver transplantation (standard caval interposition or “piggy-back” caval sparing technique), bypass utilization for liver transplantation (none, VVB, CPB), donor heart ischemic time, donor liver ischemic time, vasoactive infusions present 10 min after CPB separation after cardiac transplantation, vasoactive infusions used 10 min after recirculation of the hepatic graft, intraaortic balloon pump use, antifibrinolytic use, autologous cell salvage (volume), red blood cell transfusion (unit), fresh frozen plasma transfusion (units), platelet transfusions (apheresis units), and cryoprecipitate transfusion (number of pooled units). Each patient record was examined for the after postoperative findings: transfusion within 48 hr of surgery (red blood cells, fresh frozen plasma, platelets, and cryoprecipitate), number and type of subsequent procedures or operations performed during hospitalization, duration of mechanical ventilation, tracheostomy performed, requirement of dialysis, ICU length of stay, hospital length of stay, death within 30 days of transplantation, and death before hospital discharge.

REFERENCES 1. Starzl TE, Bilheimer DW, Bahnson HT, et al. Heart-liver transplantation in a patient with familial hypercholesterolaemia. Lancet 1984;1:1382. 2. Cannon RM, Hughes MG, Jones CM, et al. A review of the United States experience with combined heart-liver transplantation. Transpl Int 2012;25:1223. 3. Gandhi SK, Reyes J, Webber SA, et al. Case report of combined pediatric heart-lung-liver transplantation. Transplantation 2002;73:1968. 4. Barshes NR, Udell IW, Joyce DL, et al. A pooled analysis of posttransplant survival following combined heart-liver transplantation. Transplantation 2007;83:95. 5. Diaz GC, Renz JF, Nishanian E, et al. Anesthetic management of combined heart-liver transplantation. J Cardiothorac Vasc Anesth 2007;21:253. 6. Nagpal AD, Chamogeorgakis T, Shafii AE, et al. Combined heart and liver transplantation: the Cleveland Clinic experience. Ann Thorac Surg 2013;95:179. 7. Faenza S, Arpesella G, Bernardi E, et al. Combined liver transplants: main characteristics from the standpoint of anesthesia and support in intensive care. Transplant Proc 2006;38:1114. 8. Eyraud D, Ben Menna M, Vaillant JC, et al. Perioperative management of combined heart-liver transplantation in patients with cirrhosis, renal insufficiency, or pulmonary hypertension. Clin Transplant 2011;25:228. 9. Befeler AS, Schiano TD, Lissoos TW, et al. Successful combined liverheart transplantation in adults: report of three patients and review of the literature. Transplantation 1999;68:1423. 10. Barreiros AP, Post F, Hoppe-Lotichius M, et al. Liver transplantation and combined liver-heart transplantation in patients with familial amyloid polyneuropathy: a single-center experience. Liver Transpl 2010;16:314. 11. Raichlin E, Daly RC, Rosen CB, et al. Combined heart and liver transplantation: a single-center experience. Transplantation 2009;88:219. 12. Daly RC, Topilsky Y, Joyce L, et al. Combined heart and liver transplantation: protection of the cardiac graft from antibody rejection by initial liver implantation. Transplantation 2013;95:e2. 13. Porrett PM, Desai SS, Timmins KJ, et al. Combined orthotopic heart and liver transplantation: the need for exception status listing. Liver Transpl 2004;10:1539. 14. Manez R, Kelly RH, Kobayashi M, et al. Immunoglobulin G lymphocytotoxic antibodies in clinical liver transplantation: studies toward further defining their significance. Hepatology 1995;21:1345. 15. McMillan RW, Gelder FB, Zibari GB, et al. Soluble fraction of class I human histocompatibility leukocyte antigens in the serum of liver transplant recipients. Clin Transplant 1997;11:98. 16. Starzl TE, Valdivia LA, Murase N, et al. The biological basis of and strategies for clinical xenotransplantation. Immunol Rev 1994;141:213. 17. Dar W, Agarwal A, Watkins C, et al. Donor-directed MHC class I antibody is preferentially cleared from sensitized recipients of combined liver/kidney transplants. Am J Transplant 2011;11:841. 18. Taner T, Gandhi MJ, Sanderson SO, et al. Prevalence, course and impact of HLA donor-specific antibodies in liver transplantation in the first year. Am J Transplant 2012;12:1504. 19. Colvin RB. C4d in liver allografts: a sign of antibody-mediated rejection? Am J Transplant 2006;6:447. 20. Olausson M, Mjornstedt L, Norden G, et al. Successful combined partial auxiliary liver and kidney transplantation in highly sensitized cross-match positive recipients. Am J Transplant 2007;7:130. 21. Bernier PL, Grenon M, Ergina P, et al. Combined simultaneous heart and liver transplantation with complete cardiopulmonary bypass support. Ann Thorac Surg 2007;83:1544. 22. Rauchfuss F, Breuer M, Dittmar Y, et al. Implantation of the liver during reperfusion of the heart in combined heart-liver transplantation: own experience and review of the literature. Transplant Proc 2011;43:2707. 23. Jovine E, Mazziotti A, Grazi GL, et al. Piggy-back versus conventional technique in liver transplantation: report of a randomized trial. Transpl Int 1997;10:109. 24. Fonouni H, Mehrabi A, Soleimani M, et al. The need for venovenous bypass in liver transplantation. HPB (Oxford) 2008;10:196. 25. Gurusamy KS, Koti R, Pamecha V, et al. Veno-venous bypass versus none for liver transplantation. Cochrane Database Syst Rev 2011;10: CD007712. 26. Nuttall GA, Oliver WC, Santrach PJ, et al. Efficacy of a simple intraoperative transfusion algorithm for nonerythrocyte component utilization after cardiopulmonary bypass. Anesthesiology 2001;94:773.

Copyright © 2014 Wolters Kluwer Health, Inc. All rights reserved.

The perioperative management of patients undergoing combined heart-liver transplantation.

Combined heart-liver transplantation (CHLT) is an uncommonly performed procedure for patients with coexisting cardiac and liver disease...
175KB Sizes 1 Downloads 4 Views